NAD+ Supplements and Infusions: What Rises in the Blood and What the Evidence Shows

The drip bag hanging beside a reclining chair at a wellness lounge looks like something borrowed from an oncology ward, and that is part of its appeal. Search interest in the nad supplement and in “nad infusion” has climbed again this year, pushed along by celebrity podcasts, a run of longevity influencers posting their lab results, and a steady stream of small clinical trials that make headlines long before they make guidelines. As of September 2026, the phrase most people type is not “what is NAD” but “does it work.”

That question deserves a straighter answer than the marketing gives it. The honest version has two halves. First: yes, these products do change a number on a blood test, and that number is real. Second: no human trial has yet shown that changing the number changes how long or how well people live.

This piece walks through what actually rises in the blood, what stays stubbornly the same, and how strong the evidence is at each step. Where the science is thin, we say so plainly.

What does an NAD supplement actually do in the body?

Start with the molecule itself. NAD+ stands for nicotinamide adenine dinucleotide, a coenzyme, meaning a helper molecule that enzymes need in order to work. Every cell in the body carries it, and it does two very different jobs.

The first job is traffic control for energy. NAD+ accepts electrons stripped from food and hands them to the mitochondria, the tiny power stations inside cells, where they help generate ATP, the chemical currency cells spend on everything from muscle contraction to memory. In that role NAD+ is recycled thousands of times a day; it is not used up so much as passed around.

The second job is where the longevity story comes from. Several families of enzymes actually consume NAD+ as fuel. Sirtuins, a group of proteins that switch genes on and off in response to stress and nutrition, need it. So do PARPs, enzymes that patch damaged DNA. So does CD38, an enzyme on immune cells that breaks NAD+ down as part of inflammatory signaling. When these consumers are busy, the cell’s NAD+ pool shrinks.

An nad supplement does not usually contain NAD+ that survives digestion. Instead, it supplies a precursor, a smaller molecule the body can convert into NAD+. The two most marketed are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both are chemically related to niacin, vitamin B3, which the body has used to make NAD+ for as long as humans have eaten food.

So the plain answer to “what does the supplement do” is this: it gives cells extra raw material for a coenzyme they already make. Whether cells in an otherwise healthy adult were short of that raw material in the first place is a separate question, and the one the evidence has not settled.

Why NAD+ levels fall with age, and how sure we are

The idea that NAD+ declines with age is repeated so often that it sounds like settled fact. The human data are thinner than the confidence suggests.

Most of the decline story comes from rodents, where tissue NAD+ in liver, muscle, and brain drops measurably between young adulthood and old age, and where enzymes such as CD38 become more active in aging tissue. In mice, restoring NAD+ improves several markers of aging, from muscle stem cell function to insulin sensitivity. That is solid preclinical science.

In humans, the evidence is observational, which means researchers measured NAD+ in people of different ages and compared, rather than following anyone over time. A frequently cited study of skin samples found lower NAD+ and higher markers of oxidative stress in older donors. Plasma and blood-cell studies have found similar trends, though with wide overlap between age groups: some 70-year-olds have blood NAD+ comparable to people half their age.

Why might levels fall? Three mechanisms are plausible and not mutually exclusive. Chronic low-grade inflammation raises CD38 activity, which eats NAD+. Accumulating DNA damage keeps PARP enzymes busy, and they consume NAD+ too. And the salvage pathway, the recycling loop that rebuilds NAD+ from nicotinamide, may slow with age.

None of this proves that a lower blood NAD+ level causes aging rather than accompanying it. A shrinking NAD+ pool could be a symptom of cellular stress rather than a driver, in which case topping it up would be like refilling the coolant on an engine that is overheating for a different reason. Researchers take the hypothesis seriously enough to run trials. They do not yet take it as established enough to recommend anything.

What changed recently

The current wave of interest sits on a decade of small trials, each adding a piece.

In 2018, a randomized, placebo-controlled crossover trial in healthy middle-aged and older adults, published in Nature Communications, showed that six weeks of oral NR raised NAD+ in blood cells by about 60 percent and was well tolerated. It found no significant change in most physiological outcomes, though a trend toward lower blood pressure caught attention. That study is still the anchor for the safety claim.

In 2019, a small pharmacokinetic study in Frontiers in Aging Neuroscience gave a single intravenous NAD+ infusion over several hours and tracked what appeared in the blood. It remains the only published human trial of the nad infusion itself, and its findings, covered below, are not what most drip lounges advertise.

Also in 2019, a Cell Reports trial in older men measured NAD+ in muscle biopsies after NR and found a richer NAD+ metabolome and lower circulating inflammatory markers, but no improvement in mitochondrial energy output.

In 2021, a Science paper reported that NMN improved muscle insulin sensitivity in a small group of postmenopausal women with prediabetes, without changing weight or fasting glucose. It is the most positive metabolic result to date and also one of the smallest.

In 2022, a phase 1 trial in early Parkinson’s disease, published in Cell Metabolism, showed that oral NR raised NAD+ in the brain as measured by magnetic resonance spectroscopy, a scan that reads chemical signatures rather than shapes. A larger follow-up trial has since been completed; readers should look for its peer-reviewed publication rather than social media summaries.

As of September 2026, no NAD+ precursor or infusion has been approved by any major regulator to treat or prevent disease. Everything on the shelf is sold as a supplement or offered as an elective wellness service.

NAD supplement types compared: NR, NMN, niacin, and oral NAD+

Shoppers meet at least five products wearing the NAD label, and they are not interchangeable. The table below summarizes what human trials have measured for each.

Form	What it becomes in the body	Blood NAD+ change in trials	Strength of evidence
Nicotinamide riboside (NR)	Converted to NMN, then NAD+	Rose roughly 40 to 100 percent in blood cells over weeks	Several small randomized trials; safety data strongest
Nicotinamide mononucleotide (NMN)	Enters cells directly or after conversion to NR	Rose significantly in most trials measuring it	Fewer trials than NR; one positive metabolic result
Niacin (nicotinic acid)	Enters NAD+ synthesis via a separate pathway	Raised NAD+ in one small mitochondrial-disease study	Decades of prescription use for other purposes; flushing common
Nicotinamide (niacinamide)	Recycled to NAD+ through the salvage pathway	Raises NAD+ modestly; high intake can inhibit sirtuins	Well studied as a vitamin; little longevity data
Oral NAD+ itself	Largely broken down in the gut to nicotinamide	No convincing evidence of a distinct advantage	Minimal human data

Two patterns matter. The first is that NR and NMN, the expensive newcomers, are the only forms with repeated randomized human measurements of blood NAD+. The second is that ordinary niacin and nicotinamide, forms of vitamin B3 sold for decades, also feed the same pool, which is why the NIH Office of Dietary Supplements treats them all as part of one nutrient family.

Worth noting: whether NMN can legally be sold as a dietary supplement in the United States has been contested, and the regulatory position has shifted more than once. Anyone buying it should check the current status rather than assume.

What rises in the blood after taking an NAD supplement

Here is the part that is not in dispute. Give healthy adults NR or NMN for a few weeks and measure NAD+ inside peripheral blood mononuclear cells, the white blood cells labs use as a stand-in for tissue, and the level climbs. In the 2018 crossover trial it rose about 60 percent. In dose-ranging studies it rose in step with intake and plateaued, meaning more precursor did not keep pushing the number higher indefinitely.

Several other molecules rise alongside it, and they tell their own story. Nicotinic acid adenine dinucleotide, or NAAD, a close chemical cousin, jumps sharply and has become the most sensitive lab marker that a person is actually taking a precursor. Methylnicotinamide, a breakdown product the body excretes in urine, also climbs, evidence that a good share of what is swallowed is being processed and discarded rather than stored.

Variation between people is large. In pharmacokinetic work, some participants doubled their blood NAD+ while others barely moved, on identical intake. Gut bacteria, which can strip precursors down to nicotinamide before absorption, are one suspected reason. Baseline diet is another; someone already eating plenty of vitamin B3 has less room to rise.

Timing matters as well. Blood NAD+ takes days to weeks to reach its new plateau and drifts back toward baseline within a couple of weeks of stopping. There is no evidence of a lasting reset.

The measurement itself deserves a caveat. NAD+ is chemically fragile; it degrades quickly once blood is drawn unless samples are handled with care, and laboratories use different methods. Two direct-to-consumer tests on the same person can disagree by a wide margin. A single home test result, in either direction, is weak information.

NAD infusion: what actually happens in the blood during a drip

The infusion model rests on an intuitive idea: skip digestion, put NAD+ straight into a vein, and levels should surge. The only published human pharmacokinetic study says otherwise.

In that 2019 trial, healthy volunteers received intravenous NAD+ over roughly six hours while researchers sampled blood repeatedly. For the first two hours, plasma NAD+ did not rise at all. Not slowly; not at all. Only after about two hours did plasma levels begin to climb, and by then the metabolites nicotinamide and methylnicotinamide were already up, and urinary excretion of methylnicotinamide was increasing.

The likeliest explanation is that infused NAD+ is stripped apart almost as fast as it enters. Enzymes on the surface of blood and vessel cells, CD38 and CD73 among them, cleave it into fragments, mainly nicotinamide, which cells can then use to rebuild NAD+ through the salvage pathway. In other words, an nad infusion behaves biochemically much like a slow, expensive dose of vitamin B3, with a portion of the input excreted within hours.

Whether any intact NAD+ crosses into tissues from the bloodstream is unclear. Cells generally cannot import whole NAD+ across their membranes; they import precursors and build it inside. The one setting where infusions are studied with some rigor is addiction treatment, where small, uncontrolled reports date back decades. None meets the standard of a randomized trial, and the field has not produced one.

Side effects reported during infusions include chest tightness, nausea, cramping, and a feeling of pressure, often severe enough that clinics slow the drip. These are usually attributed to the rapid release of nicotinamide and to NAD+ acting on purinergic receptors, signaling sites on cells that respond to nucleotides. They resolve when the rate is reduced, but they are a reminder that this is a pharmacologically active procedure being offered outside a trial.

Is blood NAD+ the same as NAD+ in muscle, brain, and organs?

Blood is easy to sample, which is why nearly every trial reports it. It is also a poor proxy for the tissues people actually care about.

The best human evidence comes from studies willing to take a muscle biopsy. In the 2019 Cell Reports trial, older men taking NR for three weeks showed a clear shift in the NAD+ metabolome of skeletal muscle, with more of the related molecules present, yet muscle mitochondrial function measured directly did not improve. Blood levels went up; the machinery the supplement was supposed to power ran no differently.

A separate trial in men with obesity found NR raised blood NAD+ without changing insulin sensitivity, resting energy expenditure, or muscle mitochondrial respiration. Another in overweight adults found no change in insulin sensitivity either, though it did report small shifts in body composition and muscle acetylcarnitine, a molecule involved in fat metabolism. Those secondary findings are interesting, not conclusive.

The brain is harder still. The 2022 Parkinson’s phase 1 trial used magnetic resonance spectroscopy and did detect a rise in brain NAD+ after oral NR in a subset of participants, alongside changes in gene expression related to mitochondria and inflammation. That is the strongest evidence that an oral precursor reaches a deep tissue in humans. It was a 30-person study lasting 30 days.

Why the mismatch between blood and tissue? Each organ regulates its own NAD+ pool, setting production and consumption according to local demand. Flooding the supply does not force an organ to keep more on hand, much as delivering extra flour does not make a bakery produce more bread if the ovens are the constraint. For most people, blood NAD+ is a receipt that the precursor was absorbed. It is not a readout of what the heart or liver is doing with it.

What the evidence actually says, graded by strength

Evidence comes in tiers, and honesty means labeling them.

Strong (multiple randomized controlled trials, consistent results): Oral NR and NMN raise NAD+ and related metabolites in blood cells within weeks in healthy adults. Both are well tolerated over periods of up to several months, with adverse events similar to placebo in most trials. This is about as settled as supplement science gets.

Moderate (randomized trials, but small, short, or inconsistent): Modest reductions in some circulating inflammatory markers have appeared in more than one trial. Improved muscle insulin sensitivity was seen in one trial of postmenopausal women with prediabetes but not replicated in trials of men with obesity. Small improvements in walking distance and self-rated sleep quality have been reported in a few NMN trials of older adults, with effect sizes that could plausibly be noise or expectation.

Weak (single trials, uncontrolled studies, or surrogate outcomes only): Brain NAD+ elevation in Parkinson’s disease. Any effect on blood pressure or arterial stiffness. Any effect on fatigue in the general population. Any benefit from an NAD infusion for any condition.

Absent (no human data): Extended lifespan. Reversal of biological age. Prevention of dementia, heart disease, or cancer. Improved physical performance in athletes. Every claim in this row rests on mouse studies, mechanism, or testimonials.

One more grade belongs here: the evidence on harm. Short-term safety looks reassuring. Long-term safety, meaning years of daily use, has simply not been studied in people. That is a gap, not a reassurance.

The pattern across every tier is the same. The closer an outcome sits to the supplement itself, the stronger the evidence; the closer it sits to something a person would actually notice in daily life, the weaker it becomes.

NAD supplement for energy and fatigue: what trials found

“More energy” is the most common reason people buy an nad supplement, and it is the claim with the largest gap between mechanism and measurement.

The mechanism is real enough. NAD+ shuttles electrons in the mitochondria, so a cell starved of it would generate ATP less efficiently. The leap comes in assuming that healthy adults are starved of it and that fatigue reflects that shortage. Fatigue is one of the least specific symptoms in medicine, tied to sleep debt, mood, thyroid function, anemia, medication effects, infection, and dozens of other causes that have nothing to do with a coenzyme.

Trials that measured energy directly are few. Studies using questionnaires in older adults have occasionally reported small improvements in self-rated vitality or sleepiness, but these were secondary outcomes in trials designed to measure something else, the kind of finding that surfaces by chance when a study collects twenty variables. Trials that measured objective markers, such as muscle mitochondrial respiration or resting metabolic rate, found nothing.

Chronic fatigue syndrome, now often called myalgic encephalomyelitis, has attracted interest because mitochondrial dysfunction is one hypothesis for the illness. A handful of very small studies have tested NADH, a reduced form of the coenzyme, sometimes combined with other supplements, with mixed and unreplicated results. No major guideline recommends it.

A practical point often missed: most people taking these products also start paying attention to sleep, exercise, and diet at the same time, because they have decided to invest in their health. Feeling better afterward is real; attributing it to the capsule is the uncertain part. Placebo responses in fatigue trials routinely reach 20 to 30 percent.

Anyone whose fatigue is new, worsening, or accompanied by other changes needs a medical evaluation before a supplement, not after. Unexplained tiredness is one of the ways serious conditions first announce themselves.

Metabolism, blood sugar, and weight: is NAD+ like Ozempic?

The comparison shows up in search because both have become shorthand for “the thing everyone is taking.” Biologically they have almost nothing in common.

Semaglutide, sold under brand names including Ozempic, is a prescription medicine that mimics GLP-1, a gut hormone that slows stomach emptying, signals fullness to the brain, and prompts insulin release after meals. Its effects on blood sugar and body weight have been demonstrated in large randomized trials involving tens of thousands of participants followed for years, including trials measuring heart attacks and strokes. It is a drug with a defined indication, a prescribing clinician, and monitoring.

NAD+ precursors are nutrient-derived supplements acting on cellular energy chemistry. The metabolic evidence consists of a few trials with a few dozen participants each. In mice, NMN and NR improve glucose handling and protect against diet-induced weight gain. In humans, the one positive trial found better muscle insulin sensitivity in postmenopausal women with prediabetes, a change measured by a research technique called a hyperinsulinemic-euglycemic clamp, without any change in weight, fasting glucose, or HbA1c, the three-month average blood sugar marker. Two trials in men with obesity found no metabolic benefit.

No trial has shown that an nad supplement causes meaningful weight loss. None has measured cardiovascular outcomes. Any suggestion that it is a natural alternative to a prescription GLP-1 medicine is not supported by anything in the published literature.

For people with prediabetes, type 2 diabetes, or obesity who are curious about NAD+ precursors, the relevant question is not whether to swap one for the other but whether adding a supplement of uncertain benefit makes sense alongside proven approaches. That is a conversation for the treating clinician, particularly for anyone already taking glucose-lowering medicines, where any effect on insulin sensitivity, however small, is something the prescriber should know about.

Brain health, Parkinson's, and aging: where the research is heading

If NAD+ precursors ever earn a place in medicine, the first door they are likely to open is neurological.

The reasoning is specific. Neurons are among the most energy-hungry cells in the body, and mitochondrial failure is a recognized feature of Parkinson’s disease, where the cells that produce dopamine in a region called the substantia nigra die off over years. Mouse and cell models of Parkinson’s have repeatedly shown that boosting NAD+ protects those neurons. That is why the 2022 phase 1 trial in newly diagnosed patients mattered: it showed that oral NR could raise brain NAD+ on spectroscopy and shift gene activity related to inflammation and mitochondria, with a hint, and only a hint, of milder symptom scores in those whose brain NAD+ rose most.

A follow-up trial designed to test whether that translates into slower progression over a year has been run with several hundred participants. Its results, once fully published and scrutinized, will be the single most informative piece of NAD+ evidence to date, positive or negative. Until then, the brain findings sit firmly in the exploratory column.

Beyond Parkinson’s, small studies have looked at NR in mild cognitive impairment, in a rare genetic condition called ataxia telangiectasia, and in Alzheimer’s disease, mostly measuring biomarkers rather than thinking or memory. Nothing conclusive has emerged.

On aging itself, the honest position is that no human trial can measure lifespan on a research timeline, so studies lean on surrogate markers: arterial stiffness, grip strength, walking speed, inflammatory proteins, epigenetic clocks that estimate biological age from DNA methylation patterns. Results on these have been small and inconsistent. Epigenetic clock changes in particular are easy to over-read; the clocks were built to correlate with age, not to prove that moving them moves health.

Watch the Parkinson’s data. It is the one place where the question is being asked properly.

What is the downside of taking NAD? Side effects, safety, and unknowns

The downside comes in three layers: what is known, what is suspected, and what has never been checked.

Known effects are mild in short trials. Nausea, bloating, loose stools, headache, and muscle aches have been reported at rates close to placebo for NR and NMN. Ordinary niacin causes flushing, a warm, red, itchy skin reaction, in many people; the other forms generally do not. Infusions, as noted, can cause chest pressure, cramping, and nausea during the drip. A lab finding that recurs in several trials is a modest rise in methylated metabolites in urine, which is expected chemistry rather than harm, though it has raised a theoretical question about depleting methyl groups the body uses elsewhere.

Suspected concerns come mostly from animal work and deserve to be stated without exaggeration. NAD+ fuels cell growth, and tumors are hungry for it. In a 2023 mouse study of triple-negative breast cancer, NR supplementation was associated with more brain metastases. Other preclinical work has found NAD+ precursors either promoting or suppressing tumor growth depending on the model. No human trial has shown increased cancer risk, but none has been long enough or large enough to detect one. People with a current or recent cancer diagnosis should not take these products without discussing it with their oncology team.

Unknowns are the largest layer. There are no multi-year safety data. There is almost no information on use during pregnancy or breastfeeding, in children, in people with kidney or liver disease, or alongside common medicines. Nicotinamide at high intake can inhibit sirtuins, the very enzymes the supplement is meant to support, which raises the possibility that more is not better. Product quality is another variable; independent testing has found supplements whose actual content differs from the label.

None of this makes an nad supplement dangerous on the evidence available. It makes it a product with a short safety record being used by many people for a long time, which is a different kind of risk, and one worth naming.

Common myths about NAD+ supplements and infusions

Viral claims tend to be one true fact stretched past what it can bear. Here are the ones that circulate most.

“NAD+ reverses aging.” In mice, restoring NAD+ improves some markers of aging. In humans, no trial has measured lifespan, and surrogate markers have moved little or not at all. Raising a coenzyme level is not the same as turning back a clock.

“Infusions work better because they bypass the gut.” The only human pharmacokinetic study found plasma NAD+ did not rise for about two hours during a slow infusion, while breakdown products appeared quickly. The nad infusion appears to be dismantled in the bloodstream and rebuilt inside cells from nicotinamide, the same route a capsule of vitamin B3 takes.

“You can feel it working within days.” Blood NAD+ takes days to weeks to plateau. Rapid subjective effects are more consistent with expectation, hydration from an IV, or the flush of niacin than with cellular energy chemistry.

“Everyone over 40 is deficient.” Human data show a trend toward lower levels with age, with wide overlap between age groups and no agreed threshold for deficiency. True vitamin B3 deficiency, pellagra, is rare in countries with fortified grains and produces distinct skin, gut, and neurological symptoms.

“NMN is banned, so it must be powerful.” Regulatory disputes over NMN concern whether it qualifies as a dietary supplement or was first studied as a drug, a legal classification question. They say nothing about efficacy.

“It boosts metabolism and burns fat.” No human trial has shown weight loss. One found better muscle insulin sensitivity without weight change; others found no metabolic effect.

“A blood test proves you need it.” NAD+ is unstable once drawn, methods vary between labs, and there is no clinical reference range tied to health outcomes. A low reading has no established medical meaning.

Is NAD+ really worth taking? What raises NAD+ without a supplement

Strip away the marketing and the question becomes narrower: is a well-tolerated supplement with proven effects on a blood marker and unproven effects on health worth a person’s money and attention? Reasonable people, and reasonable clinicians, land in different places.

What matters most, in our reading of the evidence, is that the body already has robust ways to raise and protect its NAD+ pool, and those ways have the outcome data supplements lack.

Exercise is the clearest. Endurance training increases the activity of NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, in skeletal muscle, and trained older adults show muscle NAMPT levels closer to those of young people. Regular physical activity also has decades of randomized and observational evidence for lower cardiovascular mortality, something no nad supplement can claim.

Sleep and circadian rhythm matter because NAD+ synthesis runs on a daily cycle governed by clock genes; chronic sleep disruption flattens that cycle in animal studies. Avoiding sustained overconsumption of calories matters because caloric excess raises NAD+ consumption by inflammatory pathways, while modest energy restriction increases sirtuin activity in multiple species.

Diet supplies the raw material. Poultry, fish, beef, peanuts, mushrooms, and fortified grains are rich in niacin, and the body also converts the amino acid tryptophan into NAD+. The NIH Office of Dietary Supplements notes that most adults in the United States meet or exceed their niacin requirement from food alone.

Where does that leave the capsule? For a healthy adult, it is an optional purchase with a plausible mechanism, a reassuring short-term safety record, and no demonstrated benefit on anything they would notice. For someone with a diagnosed condition, it is a question for the clinician managing that condition, not a decision to make alone. Neither answer is exciting. Both are what the evidence supports.

When to see a doctor

Supplements marketed for energy and longevity have a way of delaying medical visits, because they offer an explanation for symptoms that deserve a proper one. Certain situations call for a clinician regardless of what is in the medicine cabinet.

Talk to a doctor before starting any nad supplement or infusion if you have a current or past cancer diagnosis, are pregnant or breastfeeding, have kidney or liver disease, have diabetes or take glucose-lowering medicines, take blood pressure medicines, or take any prescription medicine long term. Interactions have not been studied, and a prescriber cannot account for something they do not know about.

Seek medical evaluation, not a supplement, for fatigue that is new, persistent beyond a few weeks, or worsening, especially if it comes with unexplained weight loss, night sweats, fever, shortness of breath, palpitations, persistent low mood, or changes in thinking or memory. These are red-flag combinations that need investigation.

Stop the product and contact a clinician if you develop persistent nausea or vomiting, yellowing of the skin or eyes, dark urine, severe or lasting abdominal pain, unusual bruising or bleeding, a widespread rash, or swelling of the face or throat. Seek emergency care for chest pain, difficulty breathing, fainting, or signs of a severe allergic reaction.

During an infusion, report chest tightness, cramping, nausea, or a racing heart to the person administering it immediately, and do not accept reassurance that these are “normal” without the rate being adjusted and your vital signs checked. Ask beforehand who is medically responsible if something goes wrong, what is in the bag, and how it was prepared.

Never stop or change a prescribed medicine because a supplement or a wellness provider suggests it. Every decision about adding, continuing, or stopping an NAD+ product belongs with the clinician who knows your history, and every claim a seller makes should be measured against the evidence described here.

Frequently asked questions

What does an NAD supplement do?

An NAD supplement supplies a precursor, usually nicotinamide riboside or nicotinamide mononucleotide, that cells convert into NAD+, a coenzyme used for energy production and for enzymes that repair DNA and regulate genes. In trials it raises NAD+ in blood cells within weeks. Whether that extra supply changes how cells actually perform in healthy adults is unproven; muscle studies found no improvement in mitochondrial function despite higher levels.

What is the downside of taking NAD?

Short-term side effects are mild and similar to placebo: nausea, bloating, headache, and muscle aches, plus flushing with plain niacin. The larger downside is uncertainty. There are no multi-year safety studies, no data in pregnancy or with most medicines, and mouse studies have linked NAD+ precursors to faster tumor growth in some cancer models. People with cancer, kidney or liver disease, or on prescription medicines should ask their clinician first.

Is NAD+ really worth taking?

For a healthy adult, the evidence supports a plausible mechanism and a reassuring short-term safety record but no benefit on anything a person would notice, such as energy, weight, cognition, or lifespan. Exercise, adequate sleep, and a diet with normal niacin intake raise or protect NAD+ and carry proven health outcomes. Anyone with a diagnosed condition should treat it as a question for their treating clinician rather than a personal experiment.

Is NAD+ like Ozempic?

No. Ozempic is a brand of semaglutide, a prescription GLP-1 receptor agonist with large randomized trials showing effects on blood sugar, weight, and cardiovascular events. NAD+ precursors are nutrient-derived supplements acting on cellular energy chemistry, studied in trials of a few dozen people, with no demonstrated weight loss and no cardiovascular outcome data. They are not alternatives to each other, and any question about combining them belongs with the prescribing clinician.

Is an NAD infusion better than NAD pills?

The evidence does not show that. In the only published human pharmacokinetic study, intravenous NAD+ did not raise plasma NAD+ for about two hours and was rapidly broken down into nicotinamide, which cells then use to rebuild NAD+, the same route oral precursors take. Infusions also cause chest tightness, nausea, and cramping in some people during the drip. No randomized trial has compared an NAD infusion with oral supplements or placebo for any health outcome.

How long does it take for an NAD supplement to raise blood levels?

Blood NAD+ typically rises over days and reaches a plateau within a few weeks of daily intake, then drifts back toward baseline within roughly two weeks of stopping. The size of the rise varies widely between individuals, likely because gut bacteria break down some of the precursor before absorption and because baseline diet differs. Any product promising effects within hours is describing something other than NAD+ chemistry.

What is the difference between NMN and NR?

Both are forms of vitamin B3 that the body converts into NAD+. Nicotinamide riboside is one step further from NAD+ and is converted to NMN first; nicotinamide mononucleotide is one step closer. In human trials both raise blood NAD+ to a similar degree. NR has more published safety data; NMN has the single most positive metabolic result. Neither has shown clear superiority, and neither has outcome data on health or longevity.

Do I need a blood test before taking NAD+?

No test can tell you whether you would benefit. NAD+ is chemically unstable once blood is drawn, laboratories use different methods, and there is no clinical reference range linked to health outcomes. A low reading on a direct-to-consumer test has no established medical meaning, and a high reading after supplementation confirms only that the precursor was absorbed. If a doctor suspects true vitamin B3 deficiency, they will assess it clinically rather than with an NAD+ level.

Can food raise NAD+ levels naturally?

Food supplies the raw material. Poultry, fish, beef, peanuts, mushrooms, and fortified grains are rich in niacin, and the body also converts tryptophan from protein into NAD+. According to the NIH Office of Dietary Supplements, most adults in the United States already meet their niacin requirement from diet. Exercise increases the enzyme that recycles NAD+ in muscle, and regular sleep supports its daily production cycle, both with proven health benefits that supplements lack.

Is it safe to take an NAD supplement with prescription medicines?

Interactions have not been formally studied, which is different from having been ruled out. Because one trial suggested an effect on insulin sensitivity and another hinted at blood pressure changes, people taking glucose-lowering or blood pressure medicines should tell their prescriber before starting. Anyone with cancer, kidney or liver disease, or who is pregnant or breastfeeding should not take these products without medical advice. Never stop or adjust a prescribed medicine based on a supplement.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.